Publication:
Discovery and evaluation of inhibitory activity and mechanism of arylcoumarin derivatives on Theileria annulata enolase by in vitro and molecular docking studies

dc.contributor.authorMUTLU, ÖZAL
dc.contributor.authorDANIŞ, ÖZKAN
dc.contributor.authorsYakarsonmez, Sinem; Danis, Ozkan; Mutlu, Ozal; Topuzogullari, Murat; Sariyer, Emrah; Yuce-Dursun, Basak; Turgut-Balik, Dilek
dc.date.accessioned2022-03-12T22:39:08Z
dc.date.accessioned2026-01-11T15:10:55Z
dc.date.available2022-03-12T22:39:08Z
dc.date.issued2020
dc.description.abstractIn this study, the inhibition potential of 3- and 4-arylcoumarin derivatives on Theileria annulata enolase (TaENO) was assessed for the first time in the literature. Firstly, protein stabilization analyses of TaENO were performed and it was found that the enzyme remains stable with the addition of 6 M ethylene glycol at + 4 degrees C. Inhibitor screening analyses were carried out using 25 coumarin derivatives on highly purified TaENO (> 95%), and four coumarin derivatives [4-(3,4-dimethoxyphenyl)-6,7-dihydroxy-2H-chromen-2-one (C8); 4-(3,4-dihydroxyphenyl)-7,8 dihydroxy-2H-chromen-2-one (C9); 4-(3,4-dihydroxyphenyl)-6,7-dihydroxy-2H-chromen-2 one (C21); and 3-(3,4-dihydroxyphenyl)-7,8-dihydroxy-2H-chromen-2-one (C23)] showed the highest inhibitory effects with the IC50 values of 10.450, 13.170, 8.871 and 10.863 mu M, respectively. The kinetic results indicated that these compounds inhibited the enzyme by uncompetitive inhibition. In addition, the successful binding of the most potent inhibitor (C21) into TaENO was confirmed by using MALDI-TOF mass spectrophotometry. Molecular docking analyses have predicted that C8 and C21 coumarin derivatives which showed high inhibitory effects on TaENO were interacted with high affinity to the potential regions out of the active site. Taken together, these coumarin derivatives (C8, C9, C21 and C23) are first known potent, nonsubstrate, uncompetitive inhibitors of TaENO and these results will facilitate further in vitro and in vivo analysis toward structure-based drug design studies. [GRAPHICS] .
dc.identifier.doi10.1007/s11030-019-10018-9
dc.identifier.eissn1573-501X
dc.identifier.issn1381-1991
dc.identifier.pubmed31754915
dc.identifier.urihttps://hdl.handle.net/11424/235774
dc.identifier.wosWOS:000498621700001
dc.language.isoeng
dc.publisherSPRINGER
dc.relation.ispartofMOLECULAR DIVERSITY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectStructure-based drug design
dc.subjectTheileriosis
dc.subjectDrug resistance
dc.subjectCoumarin
dc.subjectEnolase
dc.subjectEnzyme inhibition
dc.subjectGLUTATHIONE-S-TRANSFERASE
dc.subjectACCURATE DOCKING
dc.subjectALPHA-ENOLASE
dc.subjectPROTEIN
dc.subjectENZYME
dc.subjectPURIFICATION
dc.subjectGLYCEROL
dc.subjectCLONING
dc.subjectGENE
dc.subjectSTABILIZATION
dc.titleDiscovery and evaluation of inhibitory activity and mechanism of arylcoumarin derivatives on Theileria annulata enolase by in vitro and molecular docking studies
dc.typearticle
dspace.entity.typePublication
oaire.citation.endPage1164
oaire.citation.issue4
oaire.citation.startPage1149
oaire.citation.titleMOLECULAR DIVERSITY
oaire.citation.volume24

Files